| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Jan 26, 2021 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 5,477 | $120.02 | $657,371.27 | -7.8% | |
| Jan 25, 2021 | BTAI Bioxcel Therapeutics, Inc. | Yocca Frank88 | Chief Scientific Officer | Sell | 15,000 | $48.39 | $725,814.28 | -3.8% | |
| Jan 25, 2021 | LQDA Liquidia Corp | Eshelman Ventures, LLC | 10% Owner | Sell | 1,219,287 | $2.96 | $3,612,315.68 | -11.4% | |
| Jan 22, 2021 | LLY Eli Lilly & Co | Tyto Acquisition Corp | 10% Owner | Buy | 34,284,789 | $22.50 | $771,407,752.50 | -100.0% | |
| Jan 22, 2021 | LNTH Lantheus Holdings, Inc. | Maeusli Heinz Christoph | Director | Buy | 1,000 | $15.29 | $15,290.00 | +10.9% | |
| Jan 22, 2021 | SCYX Scynexis Inc | Perceptive Advisors LLC51 | 10% Owner | Sell | 599,000 | $7.86 | $4,705,430.71 | -7.0% | |
| Jan 21, 2021 | LQDA Liquidia Corp | Eshelman Ventures, LLC | 10% Owner | Sell | 328,250 | $2.96 | $972,079.55 | -5.6% | |
| Jan 21, 2021 | BSPK Bespoke Extracts, Inc. | Pollack Danil | CEO | Buy | 2,000,000 | $0.05 | $100,000.00 | +1.6% | |
| Jan 21, 2021 | EBS Emergent Biosolutions Inc. | Kramer Robert | President And CEO | Sell | 24,132 | $110.03 | $2,655,177.00 | -8.0% | |
| Jan 20, 2021 | LQDA Liquidia Corp | Eshelman Ventures, LLC | 10% Owner | Sell | 147,240 | $2.97 | $436,796.81 | -1.2% | |
| Jan 20, 2021 | COLL Collegium Pharmaceutical, Inc | Kuhlmann Shirley R.49 | EVP And General Counsel | Sell | 6,081 | $24.45 | $148,680.45 | -5.5% | |
| Jan 19, 2021 | BTAI Bioxcel Therapeutics, Inc. | O'Neill Vincent86 | Chief Medical Officer | Sell | 25,000 | $49.47 | $1,236,719.14 | -47.1% | |
| Jan 19, 2021 | LFCR Lifecore Biomedical, Inc. \de\ | Bolles Albert D. | Chief Executive Officer | Buy | 10,000 | $10.98 | $109,800.00 | +38.2% | |
| Jan 19, 2021 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, SVP &Treasurer | Sell | 6,495 | $18.67 | $121,236.97 | -6.8% | |
| Jan 15, 2021 | COLL Collegium Pharmaceutical, Inc | Dreyer Scott54 | EVP &Chief Commercial Officer | Sell | 1,322 | $22.89 | $30,260.58 | -2.9% | |
| Jan 15, 2021 | EBS Emergent Biosolutions Inc. | Kramer Robert | President And CEO | Sell | 19,026 | $106.01 | $2,016,900.60 | -12.0% | |
| Jan 15, 2021 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 215,000 | $190.80 | $41,022,861.66 | - | |
| Jan 15, 2021 | LQDA Liquidia Corp | Eshelman Ventures, LLC | 10% Owner | Sell | 27,000 | $3.01 | $81,251.10 | -0.4% | |
| Jan 15, 2021 | LNTH Lantheus Holdings, Inc. | Maeusli Heinz Christoph | Director | Buy | 1,000 | $15.80 | $15,800.00 | +12.2% | |
| Jan 15, 2021 | CVSI Cv Sciences, Inc. | Mona Michael Joseph Jr | 10% Owner | Sell | 216,600 | $0.62 | $134,959.40 | -3.7% | |
| Jan 14, 2021 | LQDA Liquidia Corp | Eshelman Ventures, LLC | 10% Owner | Sell | 37,859 | $3.02 | $114,334.61 | -0.3% | |
| Jan 13, 2021 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 210,000 | $185.97 | $39,053,064.48 | - | |
| Jan 12, 2021 | LFCR Lifecore Biomedical, Inc. \de\ | Obus Nelson | Director | Buy | 20,000 | $10.76 | $215,248.00 | +0.3% | |
| Jan 12, 2021 | LQDA Liquidia Corp | Eshelman Ventures, LLC | 10% Owner | Sell | 112,859 | $3.06 | $345,651.73 | -0.9% | |
| Jan 11, 2021 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 220,000 | $185.49 | $40,807,754.42 | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.